CD19 and acute lymphoblastic leukemia: Through optimal designs of CAR-T cells, establishing standard protocol for conditioning and infusion, better control of complications, and combination with other therapeutic options, CD19 CAR-T cells will provide a new or the ultimate solution for the treatment of refractory/relapsed ALL.